Rachelle Gorrell
Family Medicine · Saint James, MONPI 1336114800
Payments from drug & device makers
Across 226 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$649
- AstraZeneca$304
- Novo Nordisk$298
- GSK$290
- Amgen$254
- Pfizer$205
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,696100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $649 |
| AstraZeneca | 17 | $304 |
| Novo Nordisk | 17 | $298 |
| GSK | 18 | $290 |
| Amgen | 17 | $254 |
| Pfizer | 14 | $205 |
| Merck | 11 | $191 |
| Abbott | 7 | $168 |
| Otsuka America Pharmaceutical, Inc. | 8 | $166 |
| Lilly USA, LLC | 7 | $127 |
| Boehringer Ingelheim | 7 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $96 |
| Novartis | 5 | $93 |
| Exact Sciences | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Sunovion Pharmaceuticals Inc. | 9 | $53 |
| Johnson & Johnson | 3 | $50 |
| Astellas Pharma US Inc | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Apria Healthcare LLC | 2 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Eisai Inc. | 2 | $37 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 3 | $27 |
| Scilex Pharmaceuticals Inc. | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Exeltis, USA Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Ardelyx, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Valinor Pharma, LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$3,697 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 210 | $177,032 |
| MounjaroTirzepatide | 132 | $142,151 |
| OzempicSemaglutide | 102 | $126,172 |
| EliquisApixaban | 116 | $106,768 |
| FarxigaDapagliflozin Propanediol | 75 | $72,889 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $59,964 |
| TrulicityDulaglutide | 54 | $58,512 |
| LinzessLinaclotide | 74 | $54,059 |
| JanuviaSitagliptin Phosphate | 79 | $51,513 |
| XareltoRivaroxaban | 53 | $46,603 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $39,705 |
| MyrbetriqMirabegron | 68 | $37,780 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $31,923 |
| Nurtec OdtRimegepant Sulfate | 15 | $25,956 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $24,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $127 | $200,662186 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $111 | $200,012251 claims |
| Novo NordiskOzempic, Rybelsus | $298 | $139,345115 claims |
| PfizerEliquis, Nurtec Odt | $205 | $132,723131 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $304 | $127,850204 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $290 | $100,042175 claims |
| AbbVieLinzess, Vraylar, Savella | $649 | $77,22399 claims |
| MerckJanuvia, Belsomra | $191 | $59,01496 claims |
| Johnson & JohnsonXarelto | $50 | $46,60353 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $37,78068 claims |
| NovartisEntresto | $93 | $21,37428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Saint James
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.